“As some adult patients with ADHD experience insomnia, there is considerable individual variability, and an identified need for more data on the effect of prescription ADHD stimulant medications on sleep."
Category: Prescription Drugs
The FDA says that Harmony Biosciences’ drug—previously approved for excessive daytime sleepiness in narcolepsy—works for cataplexy too. Harmony’s chief medical officer explains how this impacts healthcare practitioners and patients.Read More
Though men and women can have different responses to medications—Ambien, for example, metabolizes more slowly in women, causing next-day grogginess—doctors may not know about these differences because most clinical trial data are biased toward men.Read More
A registry study involving 2 million pregnant women shows no association between modafinil and an increased risk of malformation in babies.Read More
Highlights include presentations on Xywav, a lower sodium oxybate iindicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.Read More
The data include a final analysis of the Pitolisant Expanded Access Clinical Evaluation Program, two post-hoc analyses on clinically relevant outcomes from the Phase 3 clinical trials, and analyses that further characterize the cardiac safety profile of WAKIX.Read More
Highlights include an oral presentation focusing on the long-term efficacy and safety of DAYVIGO in adults ages 65 and older with insomnia disorder from the Phase 3 clinical study.Read More
New findings confirm the persistence of a drug dose gender gap stemming from a historic disregard of the biological differences between male and female bodies.Read More
Benzodiazepines for Sleep Are Frequently Prescribed to Elderly at Hospital Discharge. New Prospective Cohort Study Links Them to Adverse Events.
Patients are vulnerable in the period after discharge, when risks and adverse reactions can result in ER visits, rehospitalization, and even death within 30 days.Read More
A new study finds about 20% of restless legs syndrome patients are prescribed doses above the recommended maximum.Read More
DAYVIGO targets orexin receptors to facilitate sleep. It’s been trialed in the elderly and in patients with common comorbidities.Read More